BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 2013;111:1394-400. [PMID: 23453459 DOI: 10.1016/j.amjcard.2013.01.287] [Cited by in Crossref: 242] [Cited by in F6Publishing: 220] [Article Influence: 26.9] [Reference Citation Analysis]
Number Citing Articles
1 Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol 2014;63:1593-603. [PMID: 24530674 DOI: 10.1016/j.jacc.2014.01.014] [Cited by in Crossref: 160] [Cited by in F6Publishing: 152] [Article Influence: 20.0] [Reference Citation Analysis]
2 Kadhi A, Mohammed F, Nemer G. The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy. Front Cardiovasc Med 2021;8:613295. [PMID: 33937353 DOI: 10.3389/fcvm.2021.613295] [Reference Citation Analysis]
3 Marchetti C, Toldo S, Chojnacki J, Mezzaroma E, Liu K, Salloum FN, Nordio A, Carbone S, Mauro AG, Das A, Zalavadia AA, Halquist MS, Federici M, Van Tassell BW, Zhang S, Abbate A. Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. J Cardiovasc Pharmacol 2015;66:1-8. [PMID: 25915511 DOI: 10.1097/FJC.0000000000000247] [Cited by in Crossref: 78] [Cited by in F6Publishing: 43] [Article Influence: 13.0] [Reference Citation Analysis]
4 Seropian IM, Sonnino C, Van Tassell BW, Biasucci LM, Abbate A. Inflammatory markers in ST-elevation acute myocardial infarction. Eur Heart J Acute Cardiovasc Care 2016;5:382-95. [PMID: 25681486 DOI: 10.1177/2048872615568965] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
5 Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) 2015;54:2134-44. [PMID: 26209330 DOI: 10.1093/rheumatology/kev269] [Cited by in Crossref: 34] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
6 Pluijmert NJ, Atsma DE, Quax PHA. Post-ischemic Myocardial Inflammatory Response: A Complex and Dynamic Process Susceptible to Immunomodulatory Therapies. Front Cardiovasc Med 2021;8:647785. [PMID: 33996944 DOI: 10.3389/fcvm.2021.647785] [Reference Citation Analysis]
7 Lazúrová I, Tomáš Ľ. Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment. Clinic Rev Allerg Immunol 2017;52:323-32. [DOI: 10.1007/s12016-016-8566-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
8 Van Tassell BW, Trankle CR, Canada JM, Carbone S, Buckley L, Kadariya D, Del Buono MG, Billingsley H, Wohlford G, Viscusi M, Oddi-Erdle C, Abouzaki NA, Dixon D, Biondi-Zoccai G, Arena R, Abbate A. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 2018;11:e005036. [PMID: 30354558 DOI: 10.1161/CIRCHEARTFAILURE.118.005036] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 16.3] [Reference Citation Analysis]
9 Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. Front Immunol 2020;11:1439. [PMID: 32655577 DOI: 10.3389/fimmu.2020.01439] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
10 Bakhta O, Blanchard S, Guihot AL, Tamareille S, Mirebeau-Prunier D, Jeannin P, Prunier F. Cardioprotective Role of Colchicine Against Inflammatory Injury in a Rat Model of Acute Myocardial Infarction. J Cardiovasc Pharmacol Ther 2018;23:446-55. [PMID: 29658326 DOI: 10.1177/1074248418763611] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
11 Bromage DI, Pareek N, Cannata A, Ameri P. Targeting Inflammation After Myocardial Infarction-Another Piece of the Puzzle. J Cardiovasc Pharmacol 2022;79:769-71. [PMID: 35289771 DOI: 10.1097/FJC.0000000000001261] [Reference Citation Analysis]
12 Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med 2014;20 Suppl 1:S43-58. [PMID: 25549233 DOI: 10.2119/molmed.2014.00232] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
13 Świątkiewicz I, Magielski P, Kubica J, Zadourian A, DeMaria AN, Taub PR. Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. Int J Mol Sci 2020;21:E807. [PMID: 31991903 DOI: 10.3390/ijms21030807] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
14 Masoud S, Lim PB, Kitas GD, Panoulas V. Sudden cardiac death in patients with rheumatoid arthritis. World J Cardiol 2017; 9(7): 562-573 [PMID: 28824786 DOI: 10.4330/wjc.v9.i7.562] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
15 Mitsis A, Kadoglou NPE, Lambadiari V, Alexiou S, Theodoropoulos KC, Avraamides P, Kassimis G. Prognostic role of inflammatory cytokines and novel adipokines in acute myocardial infarction: An updated and comprehensive review. Cytokine 2022;153:155848. [PMID: 35301174 DOI: 10.1016/j.cyto.2022.155848] [Reference Citation Analysis]
16 Toldo S, Mezzaroma E, Mauro AG, Salloum F, Van Tassell BW, Abbate A. The inflammasome in myocardial injury and cardiac remodeling. Antioxid Redox Signal 2015;22:1146-61. [PMID: 25330141 DOI: 10.1089/ars.2014.5989] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 9.8] [Reference Citation Analysis]
17 Fulop T, Witkowski JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. Seminars in Immunology 2018;40:17-35. [DOI: 10.1016/j.smim.2018.09.003] [Cited by in Crossref: 118] [Cited by in F6Publishing: 103] [Article Influence: 29.5] [Reference Citation Analysis]
18 Abbate A, Wohlford GF, Del Buono MG, Chiabrando JG, Markley R, Turlington J, Kadariya D, Trankle CR, Biondi-Zoccai G, Lipinski MJ, Van Tassell BW. Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur Heart J Cardiovasc Pharmacother 2021:pvab075. [PMID: 34617567 DOI: 10.1093/ehjcvp/pvab075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Cavagna L, Taylor WJ. The emerging role of biotechnological drugs in the treatment of gout. Biomed Res Int 2014;2014:264859. [PMID: 24839602 DOI: 10.1155/2014/264859] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med 2014;65:223-44. [PMID: 24422572 DOI: 10.1146/annurev-med-061512-150641] [Cited by in Crossref: 187] [Cited by in F6Publishing: 151] [Article Influence: 23.4] [Reference Citation Analysis]
21 Olsen MB, Gregersen I, Sandanger Ø, Yang K, Sokolova M, Halvorsen BE, Gullestad L, Broch K, Aukrust P, Louwe MC. Targeting the Inflammasome in Cardiovascular Disease. JACC Basic Transl Sci 2022;7:84-98. [PMID: 35128212 DOI: 10.1016/j.jacbts.2021.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
22 Cavalli G, Dinarello CA. Anakinra Therapy for Non-cancer Inflammatory Diseases. Front Pharmacol 2018;9:1157. [PMID: 30459597 DOI: 10.3389/fphar.2018.01157] [Cited by in Crossref: 102] [Cited by in F6Publishing: 91] [Article Influence: 25.5] [Reference Citation Analysis]
23 Avolio E, Gianfranceschi G, Cesselli D, Caragnano A, Athanasakis E, Katare R, Meloni M, Palma A, Barchiesi A, Vascotto C, Toffoletto B, Mazzega E, Finato N, Aresu G, Livi U, Emanueli C, Scoles G, Beltrami CA, Madeddu P, Beltrami AP. Ex vivo molecular rejuvenation improves the therapeutic activity of senescent human cardiac stem cells in a mouse model of myocardial infarction. Stem Cells. 2014;32:2373-2385. [PMID: 24801508 DOI: 10.1002/stem.1728] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
24 van Hout G, Jansen of Lorkeers S, Wever K, Sena E, van Solinge W, Doevendans P, Pasterkamp G, Chamuleau S, Hoefer I. Anti-inflammatory compounds to reduce infarct size in large-animal models of myocardial infarction: A meta-analysis: Anti-inflammatory compounds in preclinical MI. Evidence-based Preclinical Medicine 2014;1:e00004. [DOI: 10.1002/ebm2.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Chistiakov DA, Orekhov AN, Bobryshev YV. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability. Acta Physiol (Oxf) 2015;213:539-53. [PMID: 25515699 DOI: 10.1111/apha.12438] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 9.3] [Reference Citation Analysis]
26 Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 2014;11:255-65. [PMID: 24663091 DOI: 10.1038/nrcardio.2014.28] [Cited by in Crossref: 648] [Cited by in F6Publishing: 607] [Article Influence: 81.0] [Reference Citation Analysis]
27 Bonaventura A, Montecucco F, Dallegri F. Cellular recruitment in myocardial ischaemia/reperfusion injury. Eur J Clin Invest 2016;46:590-601. [PMID: 27090739 DOI: 10.1111/eci.12633] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 9.6] [Reference Citation Analysis]
28 Emmi G, Urban ML, Imazio M, Gattorno M, Maestroni S, Lopalco G, Cantarini L, Prisco D, Brucato A. Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. Curr Cardiol Rep 2018;20:61. [PMID: 29904899 DOI: 10.1007/s11886-018-1007-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
29 Susca MG, Hodas R, Benedek T, Benedek I, Chitu M, Opincariu D, Chiotoroiu A, Rezus C. Impact of cardiac rehabilitation programs on left ventricular remodeling after acute myocardial infarction: Study Protocol Clinical Trial (SPIRIT Compliant). Medicine (Baltimore) 2020;99:e19759. [PMID: 32311978 DOI: 10.1097/MD.0000000000019759] [Reference Citation Analysis]
30 Canada JM, Thomas GK, Trankle CR, Carbone S, Billingsley H, Van Tassell BW, Evans RK, Garten R, Weiss E, Abbate A. Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy. Cardiooncology 2020;6:2. [PMID: 32154028 DOI: 10.1186/s40959-020-0058-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Zeigler AC, Nelson AR, Chandrabhatla AS, Brazhkina O, Holmes JW, Saucerman JJ. Computational model predicts paracrine and intracellular drivers of fibroblast phenotype after myocardial infarction. Matrix Biol 2020;91-92:136-51. [PMID: 32209358 DOI: 10.1016/j.matbio.2020.03.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
32 Serhal M, Longenecker CT. Preventing Heart Failure in Inflammatory and Immune Disorders. Curr Cardiovasc Risk Rep 2014;8:392. [PMID: 26316924 DOI: 10.1007/s12170-014-0392-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Marcuzzi A, Piscianz E, Valencic E, Monasta L, Vecchi Brumatti L, Tommasini A. To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies. Int J Mol Sci 2015;16:21277-93. [PMID: 26370962 DOI: 10.3390/ijms160921277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
34 Cogle CR, Wise E, Meacham AM, Zierold C, Traverse JH, Henry TD, Perin EC, Willerson JT, Ellis SG, Carlson M, Zhao DX, Bolli R, Cooke JP, Anwaruddin S, Bhatnagar A, da Graca Cabreira-Hansen M, Grant MB, Lai D, Moyé L, Ebert RF, Olson RE, Sayre SL, Schulman IH, Bosse RC, Scott EW, Simari RD, Pepine CJ, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN). Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ Res 2014;115:867-74. [PMID: 25136078 DOI: 10.1161/CIRCRESAHA.115.304353] [Cited by in Crossref: 53] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
35 Cerisano G, Buonamici P, Valenti R, Sciagrà R, Raspanti S, Santini A, Carrabba N, Dovellini EV, Romito R, Pupi A, Colonna P, Antoniucci D. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J 2014;35:184-91. [PMID: 24104875 DOI: 10.1093/eurheartj/eht420] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 7.9] [Reference Citation Analysis]
36 Turner NA. Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). J Mol Cell Cardiol 2016;94:189-200. [PMID: 26542796 DOI: 10.1016/j.yjmcc.2015.11.002] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 15.0] [Reference Citation Analysis]
37 Rogers JD, Holmes JW, Saucerman JJ, Richardson WJ. Mechano-chemo signaling interactions modulate matrix production by cardiac fibroblasts. Matrix Biol Plus 2021;10:100055. [PMID: 34195592 DOI: 10.1016/j.mbplus.2020.100055] [Reference Citation Analysis]
38 Horii Y, Nakaya M, Ohara H, Nishihara H, Watari K, Nagasaka A, Nakaya T, Sugiura Y, Okuno T, Koga T, Tanaka A, Yokomizo T, Kurose H. Leukotriene B4 receptor 1 exacerbates inflammation following myocardial infarction. FASEB J 2020;34:8749-63. [PMID: 32385915 DOI: 10.1096/fj.202000041R] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Wang S, Su X, Xu L, Chang C, Yao Y, Komal S, Cha X, Zang M, Ouyang X, Zhang L, Han S. Glycogen synthase kinase-3β inhibition alleviates activation of the NLRP3 inflammasome in myocardial infarction. J Mol Cell Cardiol 2020;149:82-94. [PMID: 32991876 DOI: 10.1016/j.yjmcc.2020.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 De Jesus NM, Wang L, Lai J, Rigor RR, Francis Stuart SD, Bers DM, Lindsey ML, Ripplinger CM. Antiarrhythmic effects of interleukin 1 inhibition after myocardial infarction. Heart Rhythm 2017;14:727-36. [PMID: 28111350 DOI: 10.1016/j.hrthm.2017.01.027] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
41 Abouzaki NA, Christopher S, Trankle C, Van Tassell BW, Carbone S, Mauro AG, Buckley L, Toldo S, Abbate A. Inhibiting the Inflammatory Injury After Myocardial Ischemia Reperfusion With Plasma-Derived Alpha-1 Antitrypsin: A Post Hoc Analysis of the VCU-α1RT Study. J Cardiovasc Pharmacol 2018;71:375-9. [PMID: 29634656 DOI: 10.1097/FJC.0000000000000583] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
42 Freeman TL, Swartz TH. Targeting the NLRP3 Inflammasome in Severe COVID-19. Front Immunol 2020;11:1518. [PMID: 32655582 DOI: 10.3389/fimmu.2020.01518] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 49.5] [Reference Citation Analysis]
43 Cao DJ, Schiattarella GG, Villalobos E, Jiang N, May HI, Li T, Chen ZJ, Gillette TG, Hill JA. Cytosolic DNA Sensing Promotes Macrophage Transformation and Governs Myocardial Ischemic Injury. Circulation 2018;137:2613-34. [PMID: 29437120 DOI: 10.1161/CIRCULATIONAHA.117.031046] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 13.8] [Reference Citation Analysis]
44 Torp MK, Yang K, Ranheim T, Husø Lauritzen K, Alfsnes K, Vinge LE, Aukrust P, Stensløkken KO, Yndestad A, Sandanger Ø. Mammalian Target of Rapamycin (mTOR) and the Proteasome Attenuates IL-1β Expression in Primary Mouse Cardiac Fibroblasts. Front Immunol 2019;10:1285. [PMID: 31244838 DOI: 10.3389/fimmu.2019.01285] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Schofer N, Ludwig S, Rübsamen N, Schnabel R, Lackner KJ, Ruprecht HJ, Bickel C, Landmesser U, Blankenberg S, Zeller T. Prognostic impact of Interleukin-1 receptor antagonist in patients with documented coronary artery disease. Int J Cardiol 2018;257:24-9. [PMID: 29395365 DOI: 10.1016/j.ijcard.2018.01.055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
46 Hung AM, Tsuchida Y, Nowak KL, Sarkar S, Chonchol M, Whitfield V, Salas N, Dikalova A, Yancey PG, Huang J, Linton MF, Ikizler TA, Kon V. IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD. Clin J Am Soc Nephrol 2019;14:702-11. [PMID: 31015261 DOI: 10.2215/CJN.04360418] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
47 Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos J, Alexopoulos D, Pyrgakis V, Cleman MW, Manolis AS, Tousoulis D, Lekakis J. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation 2015;132:1395-403. [PMID: 26265659 DOI: 10.1161/CIRCULATIONAHA.115.017611] [Cited by in Crossref: 113] [Cited by in F6Publishing: 40] [Article Influence: 16.1] [Reference Citation Analysis]
48 Agnello F, Capodanno D. Anti-inflammatory strategies for atherosclerotic artery disease. Expert Opinion on Drug Safety. [DOI: 10.1080/14740338.2022.2036717] [Reference Citation Analysis]
49 Drakopoulou M, Soulaidopoulos S, Oikonomou G, Tousoulis D, Toutouzas K. Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Curr Vasc Pharmacol 2020;18:488-506. [PMID: 32056527 DOI: 10.2174/1570161118666200214115532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
50 Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, Gibson CM, Goto S, Katus HA, Kerneis M, Kimura T, Kunadian V, Pinto DS, Shiomi H, Spertus JA, Steg PG, Mehran R. ST-segment elevation myocardial infarction. Nat Rev Dis Primers 2019;5:39. [PMID: 31171787 DOI: 10.1038/s41572-019-0090-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
51 Ridker PM. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Circ Res 2019;124:437-50. [PMID: 30702995 DOI: 10.1161/CIRCRESAHA.118.313129] [Cited by in Crossref: 86] [Cited by in F6Publishing: 41] [Article Influence: 28.7] [Reference Citation Analysis]
52 Mylonas KS, Iliopoulos D, Nikiteas N, Schizas D. Looking for the Achilles heel of atheromatosis: could it be immunotherapy? Immunotherapy 2021;13:557-60. [PMID: 33757293 DOI: 10.2217/imt-2021-0015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Crossman D, Rothman A. The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired. J Thorac Dis 2017;9:4922-5. [PMID: 29312693 DOI: 10.21037/jtd.2017.11.96] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
54 Frangogiannis NG. Inflammation in cardiac injury, repair and regeneration. Curr Opin Cardiol 2015;30:240-5. [PMID: 25807226 DOI: 10.1097/HCO.0000000000000158] [Cited by in Crossref: 108] [Cited by in F6Publishing: 55] [Article Influence: 15.4] [Reference Citation Analysis]
55 Livshits G, Kalinkovich A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Res Rev 2019;56:100980. [PMID: 31726228 DOI: 10.1016/j.arr.2019.100980] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
56 Ridker PM. Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk. Journal of the American College of Cardiology 2018;72:3320-31. [DOI: 10.1016/j.jacc.2018.06.082] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 15.8] [Reference Citation Analysis]
57 Walkowski B, Kleibert M, Majka M, Wojciechowska M. Insight into the Role of the PI3K/Akt Pathway in Ischemic Injury and Post-Infarct Left Ventricular Remodeling in Normal and Diabetic Heart. Cells 2022;11:1553. [DOI: 10.3390/cells11091553] [Reference Citation Analysis]
58 Pappalardo F, Malara G, Montisci A. Multitarget Approach to Cardiogenic Shock after Acute Myocardial Infarction: Extracorporeal Life Support (ECLS) and Beyond. Membranes (Basel) 2021;11:87. [PMID: 33513892 DOI: 10.3390/membranes11020087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Catapano AL, Pirillo A, Norata GD. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Br J Pharmacol 2017;174:3973-85. [PMID: 28369752 DOI: 10.1111/bph.13805] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 13.4] [Reference Citation Analysis]
60 Butts B, Gary RA, Dunbar SB, Butler J. The Importance of NLRP3 Inflammasome in Heart Failure. J Card Fail 2015;21:586-93. [PMID: 25982825 DOI: 10.1016/j.cardfail.2015.04.014] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 7.9] [Reference Citation Analysis]
61 Saxena A, Russo I, Frangogiannis NG. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res 2016;167:152-66. [PMID: 26241027 DOI: 10.1016/j.trsl.2015.07.002] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 9.9] [Reference Citation Analysis]
62 Toldo S, Mezzaroma E, Bressi E, Marchetti C, Carbone S, Sonnino C, Van Tassell BW, Abbate A. Interleukin-1β Blockade Improves Left Ventricular Systolic/Diastolic Function and Restores Contractility Reserve in Severe Ischemic Cardiomyopathy in the Mouse: . Journal of Cardiovascular Pharmacology 2014;64:1-6. [DOI: 10.1097/fjc.0000000000000106] [Cited by in Crossref: 52] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
63 Van Tassell BW, Lipinski MJ, Appleton D, Roberts CS, Kontos MC, Abouzaki N, Melchior R, Mueller G, Garnett J, Canada J, Carbone S, Buckley LF, Wohlford G, Kadariya D, Trankle CR, Oddi Erdle C, Sculthorpe R, Puckett L, DeWilde C, Shah K, Angiolillo DJ, Vetrovec G, Biondi-Zoccai G, Arena R, Abbate A. Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study. Clin Cardiol 2018;41:1004-8. [PMID: 30033595 DOI: 10.1002/clc.22988] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
64 van Zuylen VL, den Haan MC, Geutskens SB, Roelofs H, Fibbe WE, Schalij MJ, Atsma DE. Post-myocardial infarct inflammation and the potential role of cell therapy. Cardiovasc Drugs Ther 2015;29:59-73. [PMID: 25583678 DOI: 10.1007/s10557-014-6568-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
65 Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289. [PMID: 24115947 DOI: 10.3389/fimmu.2013.00289] [Cited by in Crossref: 330] [Cited by in F6Publishing: 358] [Article Influence: 36.7] [Reference Citation Analysis]
66 O'Rourke SA, Dunne A, Monaghan MG. The Role of Macrophages in the Infarcted Myocardium: Orchestrators of ECM Remodeling. Front Cardiovasc Med 2019;6:101. [PMID: 31417911 DOI: 10.3389/fcvm.2019.00101] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
67 Frangogiannis NG. Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiologic and translational concepts. Discoveries (Craiova) 2015;3:e41. [PMID: 26273700 DOI: 10.15190/d.2015.33] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
68 Chen W, Xing J, Liu X, Wang S, Xing D. The role and transformative potential of IL-19 in atherosclerosis. Cytokine Growth Factor Rev 2021;62:70-82. [PMID: 34600839 DOI: 10.1016/j.cytogfr.2021.09.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Samsonov M, Bogin V, Van Tassell BW, Abbate A. Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale. J Transl Med 2021;19:169. [PMID: 33902621 DOI: 10.1186/s12967-021-02828-z] [Reference Citation Analysis]
70 Tschöpe C, Cooper LT, Torre-Amione G, Van Linthout S. Management of Myocarditis-Related Cardiomyopathy in Adults. Circ Res 2019;124:1568-83. [PMID: 31120823 DOI: 10.1161/CIRCRESAHA.118.313578] [Cited by in Crossref: 70] [Cited by in F6Publishing: 37] [Article Influence: 35.0] [Reference Citation Analysis]
71 Sánchez-Hernández CD, Torres-Alarcón LA, González-Cortés A, Peón AN. Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive Approaches. Mediators Inflamm 2020;2020:8405370. [PMID: 32410868 DOI: 10.1155/2020/8405370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
72 Danielson KM, Shah R, Yeri A, Liu X, Camacho Garcia F, Silverman M, Tanriverdi K, Das A, Xiao C, Jerosch-Herold M, Heydari B, Abbasi S, Van Keuren-Jensen K, Freedman JE, Wang YE, Rosenzweig A, Kwong RY, Das S. Plasma Circulating Extracellular RNAs in Left Ventricular Remodeling Post-Myocardial Infarction. EBioMedicine 2018;32:172-81. [PMID: 29779700 DOI: 10.1016/j.ebiom.2018.05.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
73 Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 2015;116:1254-68. [PMID: 25814686 DOI: 10.1161/CIRCRESAHA.116.302317] [Cited by in Crossref: 329] [Cited by in F6Publishing: 204] [Article Influence: 47.0] [Reference Citation Analysis]
74 Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J 2021;42:113-31. [PMID: 32176778 DOI: 10.1093/eurheartj/ehaa099] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 18.0] [Reference Citation Analysis]
75 Vinciguerra M, Romiti S, Fattouch K, De Bellis A, Greco E. Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm. J Clin Med. 2020;9. [PMID: 32635302 DOI: 10.3390/jcm9072095] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
76 Turner NA. Effects of interleukin-1 on cardiac fibroblast function: relevance to post-myocardial infarction remodelling. Vascul Pharmacol 2014;60:1-7. [PMID: 23806284 DOI: 10.1016/j.vph.2013.06.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
77 Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res 2016;118:145-56. [PMID: 26837745 DOI: 10.1161/CIRCRESAHA.115.306656] [Cited by in Crossref: 394] [Cited by in F6Publishing: 207] [Article Influence: 65.7] [Reference Citation Analysis]
78 Veziroglu EM, Mias GI. Characterizing Extracellular Vesicles and Their Diverse RNA Contents. Front Genet 2020;11:700. [PMID: 32765582 DOI: 10.3389/fgene.2020.00700] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
79 Aday AW, Ridker PM. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Front Cardiovasc Med 2019;6:16. [PMID: 30873416 DOI: 10.3389/fcvm.2019.00016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 16.7] [Reference Citation Analysis]
80 Awad F, Assrawi E, Louvrier C, Jumeau C, Georgin-Lavialle S, Grateau G, Amselem S, Giurgea I, Karabina SA. Inflammasome biology, molecular pathology and therapeutic implications. Pharmacol Ther 2018;187:133-49. [PMID: 29466702 DOI: 10.1016/j.pharmthera.2018.02.011] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 12.5] [Reference Citation Analysis]
81 Rout A, Sukhi A, Chaudhary R, Bliden KP, Tantry US, Gurbel PA. Investigational drugs in phase II clinical trials for acute coronary syndromes. Expert Opinion on Investigational Drugs 2020;29:33-47. [DOI: 10.1080/13543784.2020.1708324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
82 Li X, Deroide N, Mallat Z. The role of the inflammasome in cardiovascular diseases. J Mol Med (Berl) 2014;92:307-19. [PMID: 24638861 DOI: 10.1007/s00109-014-1144-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
83 De Luca G, Cavalli G, Campochiaro C, Tresoldi M, Dagna L. Myocarditis: An Interleukin-1-Mediated Disease? Front Immunol 2018;9:1335. [PMID: 29951067 DOI: 10.3389/fimmu.2018.01335] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
84 Soroureddin Z, Nouri-Vaskeh M, Maleki M, Baghbanzadeh A, Hajiasgharzadeh K, Taban Sadeghi M, Baradaran B. Targeted anti-inflammatory therapy is a new insight for reducing cardiovascular events: A review from physiology to the clinic. Life Sci 2020;253:117720. [PMID: 32360620 DOI: 10.1016/j.lfs.2020.117720] [Reference Citation Analysis]
85 Tucker B, Vaidya K, Cochran BJ, Patel S. Inflammation during Percutaneous Coronary Intervention-Prognostic Value, Mechanisms and Therapeutic Targets. Cells 2021;10:1391. [PMID: 34199975 DOI: 10.3390/cells10061391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Hartman MHT, Groot HE, Leach IM, Karper JC, van der Harst P. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc Med 2018;28:369-79. [PMID: 29519701 DOI: 10.1016/j.tcm.2018.02.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
87 Pellegrini C, Martelli A, Antonioli L, Fornai M, Blandizzi C, Calderone V. NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. Med Res Rev 2021;41:1890-926. [PMID: 33460162 DOI: 10.1002/med.21781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
88 O'Brien LC, Mezzaroma E, Van Tassell BW, Marchetti C, Carbone S, Abbate A, Toldo S. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med 2014;20:221-9. [PMID: 24804827 DOI: 10.2119/molmed.2014.00034] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 9.0] [Reference Citation Analysis]
89 Verweij SL, van der Valk FM, Stroes ES. Novel directions in inflammation as a therapeutic target in atherosclerosis. Curr Opin Lipidol 2015;26:580-5. [PMID: 26382552 DOI: 10.1097/MOL.0000000000000233] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
90 Liberale L, Carbone F, Camici GG, Montecucco F. IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. J Clin Med 2019;8:E1764. [PMID: 31652822 DOI: 10.3390/jcm8111764] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
91 Peng H, Wu H, Zhang G, Zhang W, Guo Y, Chang L, Chen S, Xue R, Zhang S. Expression and Clinical Prognostic Value of Platelet NLRP3 in Acute Coronary Syndrome. Int J Gen Med 2020;13:791-802. [PMID: 33116771 DOI: 10.2147/IJGM.S275481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Gronda E, Sacchi S, Benincasa G, Vanoli E, Napoli C. Unresolved issues in left ventricular postischemic remodeling and progression to heart failure: . Journal of Cardiovascular Medicine 2019;20:640-9. [DOI: 10.2459/jcm.0000000000000834] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
93 Abbate A, Dinarello CA. Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution? European Heart Journal 2015;36:337-9. [DOI: 10.1093/eurheartj/ehu369] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
94 Wagner KB, Felix SB, Riad A. Innate immune receptors in heart failure: Side effect or potential therapeutic target? World J Cardiol 2014; 6(8): 791-801 [PMID: 25228958 DOI: 10.4330/wjc.v6.i8.791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
95 Grosman-Rimon L, Billia F, Wright E, Carasso S, Elbaz-Greener G, Kachel E, Rao V, Cherney D. Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. Heart Fail Rev 2020;25:685-701. [PMID: 31637568 DOI: 10.1007/s10741-019-09860-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Ushakov A, Ivanchenko V, Gagarina A. Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling. Curr Cardiol Rev 2020;16:11-24. [PMID: 31072294 DOI: 10.2174/1573403X15666190509090832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
97 Jones DP, Patel J. Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders. Biology (Basel) 2018;7:E49. [PMID: 30453474 DOI: 10.3390/biology7040049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
98 Toldo S, Van Tassell BW, Abbate A. Interleukin-1 Blockade in Acute Myocardial Infarction and Heart Failure: Getting Closer and Closer. JACC Basic Transl Sci 2017;2:431-3. [PMID: 30062161 DOI: 10.1016/j.jacbts.2017.07.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
99 Guo S, Chen J, Chuo W, Liu L, Feng X, Lian H, Zheng L, Wang Y, Xie H, Luo L, Zheng C, Fu B, Wang W. A New Biomarkers Feature Pattern Consisting of TNF- α , IL-10, and IL-8 for Blood Stasis Syndrome with Myocardial Ischemia. Evid Based Complement Alternat Med 2013;2013:130702. [PMID: 24371451 DOI: 10.1155/2013/130702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
100 Toldo S, Quader M, Salloum FN, Mezzaroma E, Abbate A. Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac Death. Int J Mol Sci 2016;17:E958. [PMID: 27322252 DOI: 10.3390/ijms17060958] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
101 Sonnino C, Christopher S, Oddi C, Toldo S, Falcao RA, Melchior RD, Mueller GH, Abouzaki NA, Varma A, Gambill ML, Van Tassell BW, Dinarello CA, Abbate A. Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra. Mol Med 2014;20:486-9. [PMID: 25121719 DOI: 10.2119/molmed.2014.00121] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
102 Segiet OA, Piecuch A, Mielanczyk L, Michalski M, Nowalany-Kozielska E. Role of interleukins in heart failure with reduced ejection fraction. Anatol J Cardiol 2019;22:287-99. [PMID: 31789611 DOI: 10.14744/AnatolJCardiol.2019.32748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
103 Ren Z, Yang K, Zhao M, Liu W, Zhang X, Chi J, Shi Z, Zhang X, Fu Y, Liu Y, Yin X. Calcium-Sensing Receptor on Neutrophil Promotes Myocardial Apoptosis and Fibrosis After Acute Myocardial Infarction via NLRP3 Inflammasome Activation. Can J Cardiol 2020;36:893-905. [PMID: 32224080 DOI: 10.1016/j.cjca.2019.09.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
104 Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281:8-27. [PMID: 29247995 DOI: 10.1111/imr.12621] [Cited by in Crossref: 448] [Cited by in F6Publishing: 424] [Article Influence: 112.0] [Reference Citation Analysis]
105 Fragoulis GE, Soulaidopoulos S, Sfikakis PP, Dimitroulas T, D Kitas G. Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction. J Inflamm Res 2021;14:1915-31. [PMID: 34017189 DOI: 10.2147/JIR.S282691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Tokutome M, Matoba T, Nakano Y, Okahara A, Fujiwara M, Koga JI, Nakano K, Tsutsui H, Egashira K. Peroxisome proliferator-activated receptor-gamma targeting nanomedicine promotes cardiac healing after acute myocardial infarction by skewing monocyte/macrophage polarization in preclinical animal models. Cardiovasc Res 2019;115:419-31. [PMID: 30084995 DOI: 10.1093/cvr/cvy200] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
107 Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J 2018;39:2063-9. [PMID: 29584915 DOI: 10.1093/eurheartj/ehy128] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 23.3] [Reference Citation Analysis]
108 Puspitasari YM, Ministrini S, Schwarz L, Karch C, Liberale L, Camici GG. Modern Concepts in Cardiovascular Disease: Inflamm-Aging. Front Cell Dev Biol 2022;10:882211. [DOI: 10.3389/fcell.2022.882211] [Reference Citation Analysis]
109 Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation 2013;128:1910-23. [PMID: 24146121 DOI: 10.1161/CIRCULATIONAHA.113.003199] [Cited by in Crossref: 182] [Cited by in F6Publishing: 94] [Article Influence: 20.2] [Reference Citation Analysis]
110 Deftereos S, Giannopoulos G, Panagopoulou V, Bouras G, Raisakis K, Kossyvakis C, Karageorgiou S, Papadimitriou C, Vastaki M, Kaoukis A, Angelidis C, Pagoni S, Pyrgakis V, Alexopoulos D, Manolis AS, Stefanadis C, Cleman MW. Anti-Inflammatory Treatment With Colchicine in Stable Chronic Heart Failure. JACC: Heart Failure 2014;2:131-7. [DOI: 10.1016/j.jchf.2013.11.006] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
111 Mccarty S, Frishman W. Interleukin 1β: A Proinflammatory Target for Preventing Atherosclerotic Heart Disease. Cardiology in Review 2014;22:176-81. [DOI: 10.1097/crd.0000000000000022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
112 Contessotto P, Pandit A. Therapies to prevent post-infarction remodelling: From repair to regeneration. Biomaterials 2021;275:120906. [PMID: 34139506 DOI: 10.1016/j.biomaterials.2021.120906] [Reference Citation Analysis]
113 Huet F, Akodad M, Fauconnier J, Lacampagne A, Roubille F. Anti-inflammatory drugs as promising cardiovascular treatments. Expert Review of Cardiovascular Therapy 2017;15:109-25. [DOI: 10.1080/14779072.2017.1273771] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
114 Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, Mukhametshina RT, Kwek XY, Cabrera-Fuentes HA, Hausenloy DJ. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther 2018;186:73-87. [PMID: 29330085 DOI: 10.1016/j.pharmthera.2018.01.001] [Cited by in Crossref: 206] [Cited by in F6Publishing: 195] [Article Influence: 51.5] [Reference Citation Analysis]
115 Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW, Oddi C, Carbone S, Trankle CR, Roberts CS, Mueller GH, Gambill ML, Christopher S, Markley R, Vetrovec GW, Dinarello CA, Biondi-Zoccai G. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol 2015;115:288-92. [PMID: 25482680 DOI: 10.1016/j.amjcard.2014.11.003] [Cited by in Crossref: 106] [Cited by in F6Publishing: 91] [Article Influence: 15.1] [Reference Citation Analysis]
116 L’homme L, Esser N, Riva L, Scheen A, Paquot N, Piette J, Legrand-Poels S. Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. J Lipid Res. 2013;54:2998-3008. [PMID: 24006511 DOI: 10.1194/jlr.m037861] [Cited by in Crossref: 96] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
117 Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B, Hall AS, Fox K, Foley C, Banya W, Wang D, Flather MD, Crossman DC. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J 2015;36:377-84. [PMID: 25079365 DOI: 10.1093/eurheartj/ehu272] [Cited by in Crossref: 142] [Cited by in F6Publishing: 139] [Article Influence: 17.8] [Reference Citation Analysis]
118 Pinar AA, Scott TE, Huuskes BM, Tapia Cáceres FE, Kemp-harper BK, Samuel CS. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacology & Therapeutics 2020;209:107511. [DOI: 10.1016/j.pharmthera.2020.107511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
119 Mauro AG, Bonaventura A, Mezzaroma E, Quader M, Toldo S. NLRP3 Inflammasome in Acute Myocardial Infarction. J Cardiovasc Pharmacol 2019;74:175-87. [PMID: 31356555 DOI: 10.1097/FJC.0000000000000717] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
120 Abbate A, Canada JM, Van Tassell BW, Wise CM, Dinarello CA. Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity? Int J Cardiol 2014;171:e125-6. [PMID: 24418290 DOI: 10.1016/j.ijcard.2013.12.078] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
121 Milinković I, Polovina M, Simeunović DS, Ašanin M, Seferović PM. Oxidative stress and inflammation in heart failure: The best is yet to come. Eur J Prev Cardiol 2020;27:490-3. [PMID: 32013599 DOI: 10.1177/2047487319900294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
122 Shen J, Zhao M, Zhang C, Sun X. IL-1β in atherosclerotic vascular calcification: From bench to bedside. Int J Biol Sci 2021;17:4353-64. [PMID: 34803503 DOI: 10.7150/ijbs.66537] [Reference Citation Analysis]
123 Vecchié A, Del Buono MG, Chiabrando GJ, Dentali F, Abbate A, Bonaventura A. Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. Curr Cardiol Rep 2021;23:157. [PMID: 34599390 DOI: 10.1007/s11886-021-01589-x] [Reference Citation Analysis]
124 Ulland TK, Ferguson PJ, Sutterwala FS. Evasion of inflammasome activation by microbial pathogens. J Clin Invest 2015;125:469-77. [PMID: 25642707 DOI: 10.1172/JCI75254] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
125 Vallejo S, Palacios E, Romacho T, Villalobos L, Peiró C, Sánchez-Ferrer CF. The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovasc Diabetol 2014;13:158. [PMID: 25518980 DOI: 10.1186/s12933-014-0158-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
126 Biondi-Zoccai G, Garmendia CM, Abbate A, Giordano A, Frati G, Sciarretta S, Antonazzo B, Versaci F. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents. Curr Atheroscler Rep 2020;22:4. [PMID: 31932973 DOI: 10.1007/s11883-020-0819-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
127 Buckley LF, Viscusi MM, Van Tassell BW, Abbate A. Interleukin-1 blockade for the treatment of pericarditis. Eur Heart J Cardiovasc Pharmacother 2018;4:46-53. [PMID: 28633474 DOI: 10.1093/ehjcvp/pvx018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
128 Caccioppo A, Franchin L, Grosso A, Angelini F, D'Ascenzo F, Brizzi MF. Ischemia Reperfusion Injury: Mechanisms of Damage/Protection and Novel Strategies for Cardiac Recovery/Regeneration. Int J Mol Sci 2019;20:E5024. [PMID: 31614414 DOI: 10.3390/ijms20205024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
129 Buckley LF, Abbate A. Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside. BioDrugs 2018;32:111-8. [PMID: 29549570 DOI: 10.1007/s40259-018-0274-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
130 Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol 2018;15:203-14. [PMID: 29143812 DOI: 10.1038/nrcardio.2017.161] [Cited by in Crossref: 201] [Cited by in F6Publishing: 192] [Article Influence: 40.2] [Reference Citation Analysis]
131 Buckley LF, Libby P. Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes. J Cardiovasc Pharmacol 2019;74:297-305. [PMID: 31356538 DOI: 10.1097/FJC.0000000000000701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
132 Huang S, Frangogiannis NG. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br J Pharmacol 2018;175:1377-400. [PMID: 29394499 DOI: 10.1111/bph.14155] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 18.3] [Reference Citation Analysis]
133 Yura Y, Sano S, Walsh K. Clonal Hematopoiesis: A New Step Linking Inflammation to Heart Failure. JACC Basic Transl Sci 2020;5:196-207. [PMID: 32140625 DOI: 10.1016/j.jacbts.2019.08.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
134 Falcao RA, Christopher S, Oddi C, Reznikov L, Grizzard JD, Abouzaki NA, Varma A, Van Tassell BW, Dinarello CA, Abbate A. Interleukin-10 in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology 2014;172:e6-8. [DOI: 10.1016/j.ijcard.2013.12.126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
135 Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, Canada JM, Carbone S, Roberts CS, Abouzaki N, Melchior R, Christopher S, Turlington J, Mueller G, Garnett J, Thomas C, Markley R, Wohlford GF, Puckett L, Medina de Chazal H, Chiabrando JG, Bressi E, Del Buono MG, Schatz A, Vo C, Dixon DL, Biondi-Zoccai GG, Kontos MC, Van Tassell BW. Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc 2020;9:e014941. [PMID: 32122219 DOI: 10.1161/JAHA.119.014941] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 17.5] [Reference Citation Analysis]
136 Meimoun P, M’barek D, Dragomir C, Luycx-bore A, Elmkies F, Boulanger J, Zemir H, Martis S, Neykova A, Tzvetkov B, Clerc J. Incidence, facteurs associés et devenir de l’insuffisance cardiaque hospitalière compliquant l’infarctus antérieur aigu traité avec succès par angioplastie primaire. Annales de Cardiologie et d'Angéiologie 2013;62:293-300. [DOI: 10.1016/j.ancard.2013.08.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
137 Dinarello CA. Interleukin-1 Mediated Autoinflammation from Heart Disease to Cancer. In: Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. Cham: Springer International Publishing; 2019. pp. 711-25. [DOI: 10.1007/978-3-319-98605-0_39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Toldo S, Mauro AG, Cutter Z, Abbate A. Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2018;315:H1553-68. [PMID: 30168729 DOI: 10.1152/ajpheart.00158.2018] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 16.0] [Reference Citation Analysis]
139 Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M. Treating Life-Threatening Myocarditis by Blocking Interleukin-1. Crit Care Med 2016;44:e751-4. [PMID: 27031379 DOI: 10.1097/CCM.0000000000001654] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 8.8] [Reference Citation Analysis]
140 Chan YH, Ramji DP. A perspective on targeting inflammation and cytokine actions in atherosclerosis. Future Med Chem 2020;12:613-26. [PMID: 32175772 DOI: 10.4155/fmc-2019-0301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
141 El Kazzi M, Rayner BS, Chami B, Dennis JM, Thomas SR, Witting PK. Neutrophil-Mediated Cardiac Damage After Acute Myocardial Infarction: Significance of Defining a New Target Cell Type for Developing Cardioprotective Drugs. Antioxid Redox Signal 2020;33:689-712. [PMID: 32517486 DOI: 10.1089/ars.2019.7928] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
142 Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, Federici M, Van Tassell BW, Zhang S, Abbate A. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol 2014;63:316-22. [PMID: 24336017 DOI: 10.1097/FJC.0000000000000053] [Cited by in Crossref: 150] [Cited by in F6Publishing: 77] [Article Influence: 18.8] [Reference Citation Analysis]
143 Rider P, Carmi Y, Yossef R, Guttman O, Eini H, Azam T, Dinarello CA, Lewis EC. IL-1 Receptor Antagonist Chimeric Protein: Context-Specific and Inflammation-Restricted Activation. J Immunol 2015;195:1705-12. [PMID: 26157171 DOI: 10.4049/jimmunol.1501168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
144 Wohlford GF, Van Tassell BW, Billingsley HE, Kadariya D, Canada JM, Carbone S, Mihalick VL, Bonaventura A, Vecchié A, Chiabrando JG, Bressi E, Thomas G, Ho AC, Marawan AA, Dell M, Trankle CR, Turlington J, Markley R, Abbate A. Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure. J Cardiovasc Pharmacol 2020;77:49-60. [PMID: 33235030 DOI: 10.1097/FJC.0000000000000931] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
145 Van Tassell BW, Arena R, Biondi-Zoccai G, Canada JM, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 2014;113:321-7. [PMID: 24262762 DOI: 10.1016/j.amjcard.2013.08.047] [Cited by in Crossref: 162] [Cited by in F6Publishing: 143] [Article Influence: 20.3] [Reference Citation Analysis]
146 Bomfim GF, Cau SBA, Bruno AS, Fedoce AG, Carneiro FS. Hypertension: a new treatment for an old disease? Targeting the immune system. Br J Pharmacol 2019;176:2028-48. [PMID: 29969833 DOI: 10.1111/bph.14436] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
147 Rashidi M, Wicks IP, Vince JE. Inflammasomes and Cell Death: Common Pathways in Microparticle Diseases. Trends in Molecular Medicine 2020;26:1003-20. [DOI: 10.1016/j.molmed.2020.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
148 Hegner B, Schaub T, Janke D, Zickler D, Lange C, Girndt M, Jankowski J, Schindler R, Dragun D. Targeting proinflammatory cytokines ameliorates calcifying phenotype conversion of vascular progenitors under uremic conditions in vitro. Sci Rep 2018;8:12087. [PMID: 30108259 DOI: 10.1038/s41598-018-30626-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
149 Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, Silva-Pereira C, Albino-Teixeira A, Sousa T. Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. Front Physiol 2021;12:746494. [PMID: 34707513 DOI: 10.3389/fphys.2021.746494] [Reference Citation Analysis]
150 Li B, Li W, Li X, Zhou H. Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis. Curr Pharm Des 2017;23:1216-27. [PMID: 28034355 DOI: 10.2174/1381612822666161230142931] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]
151 Lim DT, Cannella AC, Michaud KD, Mikuls TR. Cardiovascular risk and the use of biologic agents in rheumatoid arthritis. Curr Rheumatol Rep. 2014;16:459. [PMID: 25315196 DOI: 10.1007/s11926-014-0459-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
152 Mahtta D, Sudhakar D, Koneru S, Silva GV, Alam M, Virani SS, Jneid H. Targeting Inflammation After Myocardial Infarction. Curr Cardiol Rep 2020;22:110. [PMID: 32770365 DOI: 10.1007/s11886-020-01358-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
153 Talepoor AG, Fouladseresht H, Khosropanah S, Doroudchi M. Immune-Inflammation in Atherosclerosis: A New Twist in an Old Tale. EMIDDT 2020;20:525-45. [DOI: 10.2174/1871530319666191016095725] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
154 Lorenzatti AJ. Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials. Eur Cardiol 2021;16:e15. [PMID: 33976710 DOI: 10.15420/ecr.2020.51] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
155 Chan CW, Yap YN. Pharmacotherapeutic management of gout in patients with cardiac disease. Expert Opinion on Pharmacotherapy 2018;19:2011-8. [DOI: 10.1080/14656566.2018.1536747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
156 Baldrighi M, Mallat Z, Li X. NLRP3 inflammasome pathways in atherosclerosis. Atherosclerosis 2017;267:127-38. [PMID: 29126031 DOI: 10.1016/j.atherosclerosis.2017.10.027] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 17.4] [Reference Citation Analysis]
157 Bermúdez V, Rojas-Quintero J, Velasco M. The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1β and vascular inflammation. J Thorac Dis 2018;10:64-9. [PMID: 29600023 DOI: 10.21037/jtd.2017.12.47] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
158 Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M, Dagna L. Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. Front Immunol 2017;8:131. [PMID: 28232838 DOI: 10.3389/fimmu.2017.00131] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
159 Zhu YP, Hedrick CC, Gaddis DE. Hematopoietic stem cells gone rogue. Science 2017;355:798-9. [PMID: 28232539 DOI: 10.1126/science.aam7939] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
160 Askevold ET, Gullestad L, Dahl CP, Yndestad A, Ueland T, Aukrust P. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr Heart Fail Rep 2014;11:146-55. [PMID: 24477903 DOI: 10.1007/s11897-014-0185-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
161 van der Meer JW, Simon A, Dinarello CA. Comment on "Power of rare diseases: found in translation". Sci Transl Med 2014;6:219le1. [PMID: 24431110 DOI: 10.1126/scitranslmed.3007911] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
162 Schirone L, Forte M, D’ambrosio L, Valenti V, Vecchio D, Schiavon S, Spinosa G, Sarto G, Petrozza V, Frati G, Sciarretta S. An Overview of the Molecular Mechanisms Associated with Myocardial Ischemic Injury: State of the Art and Translational Perspectives. Cells 2022;11:1165. [DOI: 10.3390/cells11071165] [Reference Citation Analysis]
163 Van Linthout S, Tschöpe C. The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure. Clin Pharmacol Ther 2019;106:1198-208. [PMID: 31544235 DOI: 10.1002/cpt.1637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
164 Rout A, Tantry US, Novakovic M, Sukhi A, Gurbel PA. Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. Expert Opin Pharmacother 2020;21:1851-65. [PMID: 32659185 DOI: 10.1080/14656566.2020.1787987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
165 Bazeley P, Morales R, Tang WHW. Evidence of Clonal Hematopoiesis and Risk of Heart Failure. Curr Heart Fail Rep 2020;17:271-6. [PMID: 32772279 DOI: 10.1007/s11897-020-00476-w] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
166 Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, Sota J, Dinarello CA. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev 2021;20:102763. [PMID: 33482337 DOI: 10.1016/j.autrev.2021.102763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
167 Khan R, Rheaume E, Tardif J. Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis. Curr Atheroscler Rep 2018;20. [DOI: 10.1007/s11883-018-0754-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
168 Abbate A, Morton AC, Crossman DC. Anti-inflammatory therapies in myocardial infarction. The Lancet 2015;385:2573-4. [DOI: 10.1016/s0140-6736(15)61153-9] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
169 Mullis C, Swartz TH. NLRP3 Inflammasome Signaling as a Link Between HIV-1 Infection and Atherosclerotic Cardiovascular Disease. Front Cardiovasc Med 2020;7:95. [PMID: 32596261 DOI: 10.3389/fcvm.2020.00095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Shokoples BG, Paradis P, Schiffrin EL. P2X7 Receptors: An Untapped Target for the Management of Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2021;41:186-99. [PMID: 32998520 DOI: 10.1161/ATVBAHA.120.315116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Beltrami-Moreira M, Vromman A, Sukhova GK, Folco EJ, Libby P. Redundancy of IL-1 Isoform Signaling and Its Implications for Arterial Remodeling. PLoS One 2016;11:e0152474. [PMID: 27032103 DOI: 10.1371/journal.pone.0152474] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
172 Del Buono MG, Damonte JI, Trankle CR, Kadariya D, Carbone S, Thomas G, Turlington J, Markley R, Canada JM, Biondi-Zoccai GG, Kontos MC, Van Tassell BW, Abbate A. Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction. Sci Rep 2022;12:1254. [PMID: 35075216 DOI: 10.1038/s41598-022-05374-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
173 Burke MJ, Walmsley R, Munsey TS, Smith AJ. Receptor tyrosine kinase inhibitors cause dysfunction in adult rat cardiac fibroblasts in vitro. Toxicology in Vitro 2019;58:178-86. [DOI: 10.1016/j.tiv.2019.03.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
174 Aliaga J, Bonaventura A, Mezzaroma E, Dhakal Y, Mauro AG, Abbate A, Toldo S. Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177® (Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperfused Anterior Wall Myocardial Infarction. Molecules 2021;26:3534. [PMID: 34207886 DOI: 10.3390/molecules26123534] [Reference Citation Analysis]
175 Yin J, Wang Y, Hu H, Li X, Xue M, Cheng W, Wang Y, Li X, Yang N, Shi Y, Yan S. P2X7 receptor inhibition attenuated sympathetic nerve sprouting after myocardial infarction via the NLRP3/IL-1β pathway. J Cell Mol Med 2017;21:2695-710. [PMID: 28470940 DOI: 10.1111/jcmm.13185] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
176 Abbate A, Van Tassell BW, Christopher S, Abouzaki NA, Sonnino C, Oddi C, Carbone S, Melchior RD, Gambill ML, Roberts CS, Kontos MC, Peberdy MA, Toldo S, Vetrovec GW, Biondi-Zoccai G, Dinarello CA. Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study). Am J Cardiol 2015;115:8-12. [PMID: 25456867 DOI: 10.1016/j.amjcard.2014.09.043] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
177 Frangogiannis NG. The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol 2014;63:185-95. [PMID: 24072174 DOI: 10.1097/FJC.0000000000000003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 53] [Article Influence: 11.4] [Reference Citation Analysis]
178 Kerneis M, Nafee T, Yee MK, Kazmi HA, Datta S, Zeitouni M, Afzal MK, Jafarizade M, Walia SS, Qamar I, Pitliya A, Kalayci A, Al Khalfan F, Gibson CM. Most Promising Therapies in Interventional Cardiology. Curr Cardiol Rep 2019;21:26. [PMID: 30868280 DOI: 10.1007/s11886-019-1108-x] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
179 Cavender MA, O'Donoghue ML, Abbate A, Aylward P, Fox KA, Glaser RX, Park JG, Lopez-Sendon J, Steg PG, Sabatine MS, Morrow DA. Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. Am Heart J 2022;243:147-57. [PMID: 34508693 DOI: 10.1016/j.ahj.2021.08.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
180 Kerola AM, Rollefstad S, Semb AG. Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment. Eur Cardiol 2021;16:e18. [PMID: 34040652 DOI: 10.15420/ecr.2020.44] [Reference Citation Analysis]
181 Oprescu N, Micheu MM, Scafa-Udriste A, Popa-Fotea NM, Dorobantu M. Inflammatory markers in acute myocardial infarction and the correlation with the severity of coronary heart disease. Ann Med 2021;53:1041-7. [PMID: 34180324 DOI: 10.1080/07853890.2021.1916070] [Reference Citation Analysis]
182 Dobbe L, Rahman R, Elmassry M, Paz P, Nugent K. Cardiogenic Pulmonary Edema. Am J Med Sci 2019;358:389-97. [PMID: 31813466 DOI: 10.1016/j.amjms.2019.09.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
183 Libby P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol 2017;70:2278-89. [PMID: 29073957 DOI: 10.1016/j.jacc.2017.09.028] [Cited by in Crossref: 246] [Cited by in F6Publishing: 235] [Article Influence: 49.2] [Reference Citation Analysis]
184 Baoqi Y, Dan M, Xingxing Z, Xueqing Z, Yajing W, Ke X, Liyun Z. Effect of Anti-Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis. Front Cardiovasc Med 2022;8:812631. [DOI: 10.3389/fcvm.2021.812631] [Reference Citation Analysis]
185 Van Tassell BW, Raleigh JMV, Abbate A. Targeting Interleukin-1 in Heart Failure and Inflammatory Heart Disease. Curr Heart Fail Rep 2015;12:33-41. [DOI: 10.1007/s11897-014-0231-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
186 Quader M, Mezzaroma E, Kenning K, Toldo S. Targeting the NLRP3 inflammasome to reduce warm ischemic injury in donation after circulatory death heart. Clin Transplant 2020;34:e14044. [PMID: 32654189 DOI: 10.1111/ctr.14044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
187 Yoshida T, Friehs I, Mummidi S, del Nido PJ, Addulnour-Nakhoul S, Delafontaine P, Valente AJ, Chandrasekar B. Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-α-induced cardiomyocyte death. J Mol Cell Cardiol 2014;75:141-51. [PMID: 25108227 DOI: 10.1016/j.yjmcc.2014.07.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
188 Elsanhoury A, Tschöpe C, Van Linthout S. A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy. J Cardiovasc Transl Res 2021;14:75-87. [PMID: 32440911 DOI: 10.1007/s12265-020-10025-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
189 Huynh K, Van Tassell B, Chow SL. Predicting therapeutic response in patients with heart failure: the story of C-reactive protein. Expert Rev Cardiovasc Ther 2015;13:153-61. [PMID: 25578159 DOI: 10.1586/14779072.2015.1000307] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
190 Jahng JW, Song E, Sweeney G. Crosstalk between the heart and peripheral organs in heart failure. Exp Mol Med 2016;48:e217. [PMID: 26964833 DOI: 10.1038/emm.2016.20] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
191 Satoh T, Otsuka A, Contassot E, French LE. The inflammasome and IL-1β: implications for the treatment of inflammatory diseases. Immunotherapy 2015;7:243-54. [PMID: 25804477 DOI: 10.2217/imt.14.106] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
192 Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, Michelsen AE, Bendz B, Amundsen BH, Espevik T. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37:2406-2413. [PMID: 27161611 DOI: 10.1093/eurheartj/ehw171] [Cited by in Crossref: 145] [Cited by in F6Publishing: 142] [Article Influence: 24.2] [Reference Citation Analysis]
193 Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M, Wojtkiewicz GR, Tricot B, Iwamoto Y, Sun Y, Weissleder R, Libby P, Swirski FK, Nahrendorf M. Targeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial Infarction. Circulation 2015;132:1880-90. [PMID: 26358260 DOI: 10.1161/CIRCULATIONAHA.115.016160] [Cited by in Crossref: 134] [Cited by in F6Publishing: 88] [Article Influence: 19.1] [Reference Citation Analysis]
194 Mentkowski KI, Euscher LM, Patel A, Alevriadou BR, Lang JK. Monocyte recruitment and fate specification after myocardial infarction. Am J Physiol Cell Physiol 2020;319:C797-806. [PMID: 32877204 DOI: 10.1152/ajpcell.00330.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Onódi Z, Ruppert M, Kucsera D, Sayour AA, Tóth VE, Koncsos G, Novák J, Brenner GB, Makkos A, Baranyai T, Giricz Z, Görbe A, Leszek P, Gyöngyösi M, Horváth IG, Schulz R, Merkely B, Ferdinandy P, Radovits T, Varga ZV. AIM2-driven inflammasome activation in heart failure. Cardiovasc Res 2021:cvab202. [PMID: 34117866 DOI: 10.1093/cvr/cvab202] [Reference Citation Analysis]
196 Lin CF, Hsu KC, HuangFu WC, Lin TE, Huang HL, Pan SL. Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury. BMC Pharmacol Toxicol 2020;21:21. [PMID: 32178737 DOI: 10.1186/s40360-020-0400-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013;25:469-84. [PMID: 24275598 DOI: 10.1016/j.smim.2013.10.008] [Cited by in Crossref: 304] [Cited by in F6Publishing: 279] [Article Influence: 33.8] [Reference Citation Analysis]
198 Vanhaverbeke M, Vausort M, Veltman D, Zhang L, Wu M, Laenen G, Gillijns H, Moreau Y, Bartunek J, Van De Werf F, Devaux Y, Janssens S, Sinnaeve PR; EU-CardioRNA COST Action CA17129. Peripheral Blood RNA Levels of QSOX1 and PLBD1 Are New Independent Predictors of Left Ventricular Dysfunction After Acute Myocardial Infarction. Circ Genom Precis Med 2019;12:e002656. [PMID: 31756302 DOI: 10.1161/CIRCGEN.119.002656] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
199 Paramel GV, Sirsjö A, Fransén K. Role of genetic alterations in the NLRP3 and CARD8 genes in health and disease. Mediators Inflamm 2015;2015:846782. [PMID: 25788762 DOI: 10.1155/2015/846782] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
200 Harouki N, Nicol L, Remy-Jouet I, Henry JP, Dumesnil A, Lejeune A, Renet S, Golding F, Djerada Z, Wecker D, Bolduc V, Bouly M, Roussel J, Richard V, Mulder P. The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure. JACC Basic Transl Sci 2017;2:418-30. [PMID: 30062160 DOI: 10.1016/j.jacbts.2017.06.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
201 Cahill TJ, Choudhury RP, Riley PR. Heart regeneration and repair after myocardial infarction: translational opportunities for novel therapeutics. Nat Rev Drug Discov 2017;16:699-717. [DOI: 10.1038/nrd.2017.106] [Cited by in Crossref: 126] [Cited by in F6Publishing: 114] [Article Influence: 25.2] [Reference Citation Analysis]
202 Patoulias D, Stavropoulos K, Imprialos K, Athyros V, Grassos H, Doumas M, Faselis C. Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. Curr Vasc Pharmacol 2021;19:323-42. [PMID: 32188386 DOI: 10.2174/1570161118666200318104434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Reichert K, Pereira do Carmo HR, Galluce Torina A, Diógenes de Carvalho D, Carvalho Sposito A, de Souza Vilarinho KA, da Mota Silveira-Filho L, Martins de Oliveira PP, Petrucci O. Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism. PLoS One 2016;11:e0166845. [PMID: 27880844 DOI: 10.1371/journal.pone.0166845] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
204 Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res 2020;126:1260-80. [PMID: 32324502 DOI: 10.1161/CIRCRESAHA.120.315937] [Cited by in Crossref: 98] [Cited by in F6Publishing: 54] [Article Influence: 49.0] [Reference Citation Analysis]
205 Liang F, Wang Y. Coronary heart disease and atrial fibrillation: a vicious cycle. Am J Physiol Heart Circ Physiol 2021;320:H1-H12. [PMID: 33185113 DOI: 10.1152/ajpheart.00702.2020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Shahrivari M, Wise E, Resende M, Shuster JJ, Zhang J, Bolli R, Cooke JP, Hare JM, Henry TD, Khan A, Taylor DA, Traverse JH, Yang PC, Pepine CJ, Cogle CR; Cardiovascular Cell Therapy Research Network (CCTRN). Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function. Circ Res 2017;120:1947-57. [PMID: 28490433 DOI: 10.1161/CIRCRESAHA.116.309947] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
207 Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, Manna R, Cimaz R, Priori R, Talarico R, Gentileschi S, de Marchi G, Frassi M, Gallizzi R, Soriano A, Alessio M, Cammelli D, Maggio MC, Marcolongo R, La Torre F, Fabiani C, Colafrancesco S, Ricci F, Galozzi P, Viapiana O, Verrecchia E, Pardeo M, Cerrito L, Cavallaro E, Olivieri AN, Paolazzi G, Vitiello G, Maier A, Silvestri E, Stagnaro C, Valesini G, Mosca M, de Vita S, Tincani A, Lapadula G, Frediani B, De Benedetti F, Iannone F, Punzi L, Salvarani C, Galeazzi M, Rigante D, Cantarini L. A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Front Pharmacol 2016;7:380. [PMID: 27822185 DOI: 10.3389/fphar.2016.00380] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
208 Silvis MJM, Demkes EJ, Fiolet ATL, Dekker M, Bosch L, van Hout GPJ, Timmers L, de Kleijn DPV. Immunomodulation of the NLRP3 Inflammasome in Atherosclerosis, Coronary Artery Disease, and Acute Myocardial Infarction. J Cardiovasc Transl Res 2021;14:23-34. [PMID: 32648087 DOI: 10.1007/s12265-020-10049-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
209 Bageghni SA, Hemmings KE, Yuldasheva NY, Maqbool A, Gamboa-Esteves FO, Humphreys NE, Jackson MS, Denton CP, Francis S, Porter KE, Ainscough JF, Pinteaux E, Drinkhill MJ, Turner NA. Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction. JCI Insight 2019;5:125074. [PMID: 31393855 DOI: 10.1172/jci.insight.125074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
210 Frangogiannis NG. Cell biological mechanisms in regulation of the post-infarction inflammatory response. Curr Opin Physiol 2018;1:7-13. [PMID: 29552674 DOI: 10.1016/j.cophys.2017.09.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
211 Guerra Martinez C. P2X7 receptor in cardiovascular disease: The heart side. Clin Exp Pharmacol Physiol 2019;46:513-26. [PMID: 30834550 DOI: 10.1111/1440-1681.13079] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
212 Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 2015;131:1019-30. [PMID: 25779542 DOI: 10.1161/CIRCULATIONAHA.114.008788] [Cited by in Crossref: 161] [Cited by in F6Publishing: 98] [Article Influence: 23.0] [Reference Citation Analysis]
213 van Hout GPJ, Bosch L. The Inflammasomes in Cardiovascular Disease. Exp Suppl 2018;108:9-40. [PMID: 30536166 DOI: 10.1007/978-3-319-89390-7_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
214 Wei D, Li R, Si T, He H, Wu W. Screening and bioinformatics analysis of key biomarkers in acute myocardial infarction. Pteridines 2021;32:79-92. [DOI: 10.1515/pteridines-2020-0031] [Reference Citation Analysis]
215 Crea F, Liuzzo G. Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine. Eur Heart J 2016;37:2414-6. [PMID: 27252447 DOI: 10.1093/eurheartj/ehw207] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
216 Powers NE, Swartzwelter B, Marchetti C, de Graaf DM, Lerchner A, Schlapschy M, Datar R, Binder U, Edwards CK, Skerra A, Dinarello CA. PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. Journal of Biological Chemistry 2020;295:868-82. [DOI: 10.1016/s0021-9258(17)49941-8] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
217 Lemarié J, Boufenzer A, Popovic B, Tran N, Groubatch F, Derive M, Labroca P, Barraud D, Gibot S. Pharmacological inhibition of the triggering receptor expressed on myeloid cells-1 limits reperfusion injury in a porcine model of myocardial infarction. ESC Heart Fail 2015;2:90-9. [PMID: 28834656 DOI: 10.1002/ehf2.12029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
218 Stitham J, Rodriguez-Velez A, Zhang X, Jeong SJ, Razani B. Inflammasomes: a preclinical assessment of targeting in atherosclerosis. Expert Opin Ther Targets 2020;24:825-44. [PMID: 32757967 DOI: 10.1080/14728222.2020.1795831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
219 Liberale L, Ministrini S, Carbone F, Camici GG, Montecucco F. Cytokines as therapeutic targets for cardio- and cerebrovascular diseases. Basic Res Cardiol 2021;116:23. [PMID: 33770265 DOI: 10.1007/s00395-021-00863-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
220 Toldo S, Mezzaroma E, O'Brien L, Marchetti C, Seropian IM, Voelkel NF, Van Tassell BW, Dinarello CA, Abbate A. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol 2014;306:H1025-31. [PMID: 24531812 DOI: 10.1152/ajpheart.00795.2013] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 9.5] [Reference Citation Analysis]
221 Hernandez-Santana YE, Giannoudaki E, Leon G, Lucitt MB, Walsh PT. Current perspectives on the interleukin-1 family as targets for inflammatory disease. Eur J Immunol 2019;49:1306-20. [PMID: 31250428 DOI: 10.1002/eji.201848056] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
222 Szekely Y, Arbel Y. A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today? Cardiol Ther 2018;7:25-44. [PMID: 29417406 DOI: 10.1007/s40119-018-0104-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
223 Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, Epstein SE. Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. Journal of the American College of Cardiology 2016;67:2050-60. [DOI: 10.1016/j.jacc.2016.01.073] [Cited by in Crossref: 189] [Cited by in F6Publishing: 177] [Article Influence: 31.5] [Reference Citation Analysis]
224 Peruzzi M, Biondi-Zoccai G, Abbate A, Giordano A, Frati G. Commentary: which comes first, the phoenix or the flame? Reflections on the role of inflammation in patients undergoing lower limb revascularization for peripheral artery disease. J Endovasc Ther 2015;22:240-2. [PMID: 25809369 DOI: 10.1177/1526602815573217] [Reference Citation Analysis]
225 Powers NE, Swartzwelter B, Marchetti C, de Graaf DM, Lerchner A, Schlapschy M, Datar R, Binder U, Edwards CK 3rd, Skerra A, Dinarello CA. PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. J Biol Chem 2020;295:868-82. [PMID: 31819009 DOI: 10.1074/jbc.RA119.010340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Ajala ON, Everett BM. Targeting Inflammation to Reduce Residual Cardiovascular Risk. Curr Atheroscler Rep 2020;22. [DOI: 10.1007/s11883-020-00883-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]